Twist Bioscience Co. (NASDAQ:TWST) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Twist Bioscience Co. (NASDAQ:TWST) have been assigned an average recommendation of “Moderate Buy” from the ten ratings firms that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $54.40.

Several equities analysts recently weighed in on the stock. Barclays set a $58.00 target price on shares of Twist Bioscience and gave the company an “overweight” rating in a research note on Monday, February 3rd. JPMorgan Chase & Co. lifted their price objective on shares of Twist Bioscience from $35.00 to $40.00 and gave the company an “underweight” rating in a research report on Tuesday, February 4th. Robert W. Baird upped their target price on shares of Twist Bioscience from $48.00 to $54.00 and gave the company an “outperform” rating in a report on Tuesday, February 4th. TD Cowen reiterated a “buy” rating and set a $58.00 price target on shares of Twist Bioscience in a report on Tuesday, November 26th. Finally, Wolfe Research began coverage on Twist Bioscience in a research report on Friday, December 13th. They set an “outperform” rating and a $60.00 price target on the stock.

Twist Bioscience Trading Up 1.3 %

Shares of NASDAQ:TWST opened at $41.33 on Thursday. The company’s 50-day moving average price is $47.74 and its two-hundred day moving average price is $45.67. Twist Bioscience has a one year low of $27.41 and a one year high of $60.90. The company has a debt-to-equity ratio of 0.03, a current ratio of 4.96 and a quick ratio of 4.62. The stock has a market capitalization of $2.47 billion, a PE ratio of -12.23 and a beta of 1.87.

Twist Bioscience (NASDAQ:TWST) last released its earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.62) by $0.09. The business had revenue of $88.70 million for the quarter, compared to analyst estimates of $86.96 million. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. Twist Bioscience’s revenue was up 24.1% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.75) earnings per share. On average, equities analysts forecast that Twist Bioscience will post -2.12 EPS for the current fiscal year.

Insider Transactions at Twist Bioscience

In other Twist Bioscience news, Director Robert Chess sold 3,504 shares of Twist Bioscience stock in a transaction dated Thursday, December 5th. The shares were sold at an average price of $51.85, for a total value of $181,682.40. Following the completion of the sale, the director now owns 21,641 shares in the company, valued at $1,122,085.85. The trade was a 13.94 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Dennis Cho sold 806 shares of the stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $49.35, for a total transaction of $39,776.10. Following the transaction, the insider now owns 112,221 shares in the company, valued at approximately $5,538,106.35. The trade was a 0.71 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 37,180 shares of company stock worth $1,821,971 over the last quarter. Company insiders own 3.01% of the company’s stock.

Institutional Investors Weigh In On Twist Bioscience

Hedge funds and other institutional investors have recently made changes to their positions in the business. Signaturefd LLC increased its stake in Twist Bioscience by 63.0% during the 3rd quarter. Signaturefd LLC now owns 792 shares of the company’s stock worth $36,000 after acquiring an additional 306 shares during the period. International Assets Investment Management LLC grew its holdings in shares of Twist Bioscience by 4,418.3% during the 3rd quarter. International Assets Investment Management LLC now owns 4,925 shares of the company’s stock worth $223,000 after purchasing an additional 4,816 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Twist Bioscience by 21.9% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company’s stock worth $98,000 after purchasing an additional 381 shares during the period. China Universal Asset Management Co. Ltd. raised its stake in Twist Bioscience by 64.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 11,268 shares of the company’s stock valued at $509,000 after purchasing an additional 4,427 shares in the last quarter. Finally, SteelPeak Wealth LLC bought a new stake in Twist Bioscience during the third quarter worth about $416,000.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.